These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


458 related items for PubMed ID: 22084213

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes.
    Kaliki S, Shields CL, Rojanaporn D, Al-Dahmash S, McLaughlin JP, Shields JA, Eagle RC.
    Ophthalmology; 2013 May; 120(5):997-1003. PubMed ID: 23399379
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Management and outcome of retinoblastoma with vitreous seeds.
    Manjandavida FP, Honavar SG, Reddy VA, Khanna R.
    Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Metastatic retinoblastoma clinical features, treatment, and prognosis.
    Gündüz K, Müftüoglu O, Günalp I, Unal E, Taçyildiz N.
    Ophthalmology; 2006 Sep; 113(9):1558-66. PubMed ID: 16828510
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
    Gündüz K, Günalp I, Yalçindağ N, Unal E, Taçyildiz N, Erden E, Geyik PO.
    Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Results of a prospective study for the treatment of retinoblastoma.
    Chantada G, Fandiño A, Dávila MT, Manzitti J, Raslawski E, Casak S, Schvartzman E.
    Cancer; 2004 Feb 15; 100(4):834-42. PubMed ID: 14770442
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients.
    Shields CL, Shelil A, Cater J, Meadows AT, Shields JA.
    Arch Ophthalmol; 2003 Nov 15; 121(11):1571-6. PubMed ID: 14609913
    [Abstract] [Full Text] [Related]

  • 18. Postenucleation adjuvant therapy in high-risk retinoblastoma.
    Honavar SG, Singh AD, Shields CL, Meadows AT, Demirci H, Cater J, Shields JA.
    Arch Ophthalmol; 2002 Jul 15; 120(7):923-31. PubMed ID: 12096963
    [Abstract] [Full Text] [Related]

  • 19. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.
    Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG.
    Ophthalmology; 2007 Jan 15; 114(1):162-9. PubMed ID: 17070578
    [Abstract] [Full Text] [Related]

  • 20. The Potential Benefit of Three vs. Six Cycles of Carboplatin, Etoposide, and Vincristine in Postenucleation High-Risk Patients with IRSS Stage I Retinoblastoma.
    Ye H, Du Y, Chen R, Luo X, Mao Y, Ai S, Ma W, Ding Y, Li Q, Yang H.
    Curr Eye Res; 2016 Nov 15; 41(11):1507-1512. PubMed ID: 27158739
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 23.